english ¼Óº¸ ÀÚ·á½Ç ¼º¸í¼­ ¼­¸íÇϱ⠰ԽÃÆÇ
¹øÈ£ : 89 From :
±Û¾´³¯ : 2003-01-25 20:46:30
±Û¾´ÀÌ : Neos Á¶È¸ : 2356
Á¦¸ñ: ±Û¸®º¤ ¸ÅÃâ 8õ9¹é3½Ê¾ï¿ø

³ë¹ÙƼ½º°¡ 2003³â 1¿ù 23ÀÏ ¹ßÇ¥ÇÑ ¿¬·Êº¸°í¼­¿¡ µû¸£¸é, 2002³â ±Û¸®º¤ ¸ÅÃâÀº ÃÑ 6¾ï
1õ5¹é¸¸ ´Þ·¯ÀÔ´Ï´Ù. 2001³â 1¾ï 5õ3¹é¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ÇÏ¿´À¸´Ï, Áö±Ý±îÁö ±Û¸®º¤ÀÇ
ÃѸÅÃâÀº 7¾ï 6õ8¹é¸¸ ´Þ·¯ÀÌ°í ¿øÈ­(¿À´Ã ȯÀ²: 1163.0000)·Î´Â 893,183,983,616 ¿ø
Áï, ¾à 8õ 9¹é3½Ê¾ï¿øÀÔ´Ï´Ù. 

³ë¹ÙƼ½º´Â ±Û¸®º¤ °³¹ß ºñ¿ëÀÌ ¾à 8¾ï ´Þ·¯¶ó°í ÁÖÀåÇÑ ¹Ù Àִµ¥, °øÀûÀÚ±ÝÀ̳ª
¼¼±ÝÇýÅÃÀ» ¹Þ¾Ò°í, 3»ó ÀÓ»ó½ÇÇèºñ°¡ µéÁö ¾Ê¾Ò´Ù´Â Á¡, Ưº°ÇÑ ¸¶ÄÉÆÃÀÌ ¾ø¾îµµ ȯÀÚ¿Í
¾ð·ÐÀ» ÅëÇØ È«º¸°¡ µÇ¾ú´Ù´Â Á¡ µîÀ» °í·ÁÇϸé ÀÌ¹Ì °³¹ßºñ ȸ¼ö¸¦ Çß´Ù°í ÇÒ ¼ö
ÀÖ°Ú±º¿ä.

2002³â ±Û¸®º¤ ¸ÅÃâÀº 303%³ª Áõ°¡ÇÏ¿´°í ³ë¹ÙƼ½º Á¦Ç° °¡¿îµ¥ 5À§ ¸ÅÃâÀ»
±â·ÏÇÏ¿´½À´Ï´Ù. Èñ±ÍÁúº´ Ä¡·á¾àÀÌ ÀÌ·¸°Ô ³ôÀº ¸ÅÃâÀ» ±â·ÏÇÏ¿´´Ù´Â °ÍÀÌ
¹«¾ùÀ» ÀǹÌÇÏ´Â Áö´Â ³Ê¹«³ª ºÐ¸íÇÕ´Ï´Ù.

±Û¸®º¤ÀÇ 2002³â ¸ÅÃâ ÀÚ·á´Â
http://www.novartis.com/downloads/annual_reports/press_release_full_year_results_2002.pdf

À§ ÀÚ·á¿¡¼­ ¹ßÃéÇÑ ³»¿ëÀÔ´Ï´Ù.

Gleevec/Glivec, (+303%, US: +103%;) for chronic myeloid leukemia (CML)
and gastrointestinal stromal tumors (GIST), continued to bring benefits to
thousands of patients in more than 80 countries. Exceeding
expectations, twelve-month sales topped CHF 953 million (USD 615
million), making it Novartis¡¯ fifth biggest product. Gleevec/Glivec
has now been approved as first-line treatment in the US, EU and
Switzerland, and major progress has been achieved on eimbursement,
especially in the UK, Australia and New Zealand.


±Û¾²±â ´ä±Û¾²±â ¼öÁ¤Çϱâ Áö¿ì±â
 
ȨÀ¸·Î ÀÌÀü±Û ¸ñ·Ï ´ÙÀ½±Û
±Û¸®º¤ °¡°ÝÀÎÇÏ, ÀǾàÇ° °ø°ø¼º °­È­¸¦ À§ÇÑ °øµ¿´ëÃ¥À§¿øȸ
Korean Progressive Network Jinbo.Net No CopyRight, Just CopyLeft!!